The use of immune checkpoint inhibitors (ICI) to treat cancer patients can impact the cardiovascular system (CV) and can lead to cardiac injury/dysfunction and the development of myocarditis.

Our latest discussion features Dr Tomas Neilan (Massachusetts General Hospital, Boston, US) who presents information on the use of ICI therapy to care for patients with cancer and considers the potential CV impact. Dr Arjun Ghosh moderates the discussion.

Dr Neilan presents data on patient outcomes, fatality rates and highlights current evidence to showcase how immune therapy leads to an increase in atherosclerosis and pericardial disease. He also highlights how ICI will drive the future of cancer care and looks forward to the many phase I-III studies that are underway.

Together they discuss if physicians should be screening patients for checkpoint inhibitor therapy and the challenges around this and consider how often physicians should monitor patients for increased troponin levels, post-treatment of checkpoint inhibition?